Table 4.
Effectiveness of three consecutive monthly doses of Credelio Plus® and afoxolaner + milbemycin oxime and impact on AM total and individual FAD clinical sign scores on dogs with natural flea infestations in client owned dogs in European field study
| Study day | Treatment group | n | Total clinical signs score | Pruritus | Erythema | Scaling | Papules | Alopecia | Dermatitis/Pyodermatitis |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Credelio Plus® | 110 | 4.65 | 1.79 | 0.95 | 0.79 | 0.37 | 0.41 | 0.39 |
| Afoxolaner + Milbemycin oxime | 55 | 4.07 | 1.64 | 0.80 | 0.75 | 0.38 | 0.24 | 0.27 | |
| 14 ± 2 | Credelio Plus® | 110 | 0.89 | 0.28 | 0.09 | 0.26 | 0.02 | 0.18 | 0.06 |
| Afoxolaner + Milbemycin oxime | 55 | 0.64 | 0.31 | 0.02 | 0.15 | 0.0 | 0.11 | 0.06 | |
| 28 ± 2 | Credelio Plus® | 110 | 0.53 | 0.20 | 0.03 | 0.16 | 0.0 | 0.09 | 0.05 |
| Afoxolaner + Milbemycin oxime | 55 | 0.49 | 0.16 | 0.05 | 0.13 | 0.0 | 0.04 | 0.11 | |
| 56 ± 2 | Credelio Plus® | 110 | 0.25 | 0.08 | 0.03 | 0.08 | 0.02 | 0.02 | 0.02 |
| Afoxolaner + Milbemycin oxime | 55 | 0.19 | 0.08 | 0.02 | 0.04 | 0.0 | 0.04 | 0.02 | |
| 84 ± 2 | Credelio Plus® | 110 | 0.15 | 0.06 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 |
| Afoxolaner + Milbemycin oxime | 55 | 0.17 | 0.06 | 0.02 | 0.08 | 0.0 | 0.0 | 0.02 |